Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d'Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled "Belle of the Concours."
A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved ... Read more
The 3rd annual TRUE Love Contest of the Prostate Cancer Foundation (PCF), which features inspirational stories from patients and caregivers to raise disease awareness, has selected two winners. Chosen ... Read more
Proscia and the University of California San Francisco (UCSF) are partnering to use artificial intelligence (AI) to improve the accuracy and speed of cancer diagnoses, starting with prostate cancer. ... Read more
Concerto HealthAI and Pfizer Oncology are expanding a collaboration using real-world data (RWD) to advance study design to include a range of cancers, including prostate cancer. The expansion builds ... Read more
To foster more research projects in prostate cancer, the U.S. Congress has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) by $10 million, to $110 million, ... Read more
Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated ... Read more
CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate ... Read more